Announcement PDF ASX Release 13/11/2020 RESULTS OF ANNUAL GENERAL MEETING Perth, Australia; 13 November 2020: Emyria Limited (ASX:EMD, “Emyria” or the “Company”) advises that its 2020 Annual General Meeting was held today, 13 November 2020. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below: Poll Results Resolutions For Against Abstain 1 Adoption of Renumeration Report 33,800,011 0 39,297,619 2 Re-election of Professor Sir John Tooke 102,048,229 0 0 3 Approval of 10% Placement Facility 101,994,905 53,324 0 4 Ratification of prior issue of Placement Shares 101,927,286 153,324 97,619 5 (a) Issue of Options to Dr Michael Winlo 33,445,437 188,324 39,463,869 5 (b) Issue of Options to Dr Alistair Vickery 33,445,437 188,324 39,463,869 5 (c) Issue of Options to Mr Matt Callahan 33,445,437 188,324 39,463,869 5 (d) Issue of Options to Professor Sir John Tooke 33,445,437 188,324 39,463,869 Proxy Votes Received Resolutions For Against At Proxy Holders Discretion Abstain 1 Adoption of Renumeration Report 28,355,479 0 14,000 39,297,619 2 Re-election of Professor Sir John Tooke 96,053,098 0 14,000 0 3 Approval of 10% Placement Facility 95,999,774 53,324 14,000 0 4 Ratification of prior issue of Placement Shares 95,792,155 153,324 24,000 97,619 5 (a) Issue of Options to Dr Michael Winlo 28,000,905 188,324 14,000 39,463,869 5 (b) Issue of Options to Dr Alistair Vickery 28,000,905 188,324 14,000 39,463,869 5 (c) Issue of Options to Mr Matt Callahan 28,000,905 188,324 14,000 39,463,869 5 (d) Issue of Options to Professor Sir John Tooke 28,000,905 188,324 14,000 39,463,869 Release authorised by: Simon Robertson Company Secretary For further information Dr Michael Winlo CEO (08) 6559 2800 mwinlo@emyria.com Lexi O’Halloran Media/Investor Relations + 61 (0) 404 577 076 lexi@janemorganmanagement.com.au About Emyria (www.emyria.com) Emyria Limited creates unique data products that accelerate the development of new treatments for patients with unmet needs. Emyria achieves this by analysing the deep, deidentified clinical data gathered from its specialist clinical network – Emerald Clinics (www.emeraldclinics.com.au) – and turning that into Real-World Evidence (RWE). Emyria’s data products accelerate the development and registration of new and promising treatments for patients with unmet medical needs by providing unique, realworld insights into the safety, quality and efficacy of those unapproved treatments, in real patients in the community. Emyria’s data assets are also a source of unique IP for Emyria, which along with its remote patient monitoring technologies, data platforms and care models, further improve the quality of its RWE data assets and insights as well as the care provided to patients.